Erlotinib is a quinazoline derivative and antineoplastic agent that functions as a protein kinase inhibitor for EGFR associated tyrosine kinase.

Gefitinib is a selective tyrosine kinase receptor inhibitor used in the therapy of non-small cell lung cancer.

Cabozantinib Malate is an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity.

Axitinib is an orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the VEGF and PDGF, thereby exerting an anti-angiogenic effect.

Lapatinib is a tyrosine kinase receptor inhibitor used in the therapy of advanced breast cancer and other solid tumors.

Lenalidomide is a thalidomide analog with potential antineoplastic activity.

TP-0903 is a potent and selective AXL Inhibitor.

Mubritinib is a potent inhibitor of HER2/ErbB2.